ArticleAmerican journal of obstetrics & gynecology MFM2026
From card to cradle: examining medical cannabis purchasing among pregnant women in Arkansas.
Article in American journal of obstetrics & gynecology MFM, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
objectiveMedical cannabis (MC) use has increased among pregnant women, yet little is known about the quantity, product types, and timing of use. This study conducted a population-level analysis of MC purchasing patterns among pregnant women in Arkansas. STUDY
designThis descriptive exploratory analysis examined MC purchasing among pregnant women in Arkansas from May 11, 2019 to August 31, 2022, following MC availability. Data from three statewide data sources, the MC Card Registry (patient and qualifying condition data), MC Dispensary Database (transactions and product details), and Birth Certificate Records (maternal demographics and obstetric diagnoses), were linked with the national Social Determinants of Health Database, which provided neighborhood-level socioeconomic indicators. Descriptive statistics summarized maternal and purchasing characteristics and identified factors associated with the amount of purchased delta-9-tetrahydrocannabinol (THC), cannabis main psychoactive ingredient.
resultsOf the 72,992 pregnancies, 1185 (1.62%) included MC purchases during pregnancy. Among these, 774 (65.3%) were continuers, defined as those with MC purchases within 90 days prior to pregnancy that continued during pregnancy, and 411 (34.7%) initiated MC beginning during pregnancy. An additional 94 pregnancies purchased MC in the 90 days prior to pregnancy but discontinued by pregnancy onset. Compared to nonpurchasers, MC purchasers were more likely to be ≥30 years old (adjusted odds ratio (aOR)=1.34; P<.0001) and tobacco smokers (aOR=1.64; P<.0001) and less likely to be non-Hispanic Black (aOR=0.44; P<.0001), married (aOR=0.68; P<.0001), and privately insured (aOR=0.69; P=.0001). The mean (SD) daily THC purchased was 137.36 (170.04) mg/d. Continuers purchased 1.54 (95% CI, 1.32-1.78) times more daily THC during pregnancy than initiators and 3.84 (95% CI, 2.66-5.55) times more prepregnancy THC than discontinuers. The adjusted mean ratio (AMR) of daily THC was 1.82 (P<.0001) times higher among continuers compared to initiators, and lower for women <20 years (AMR=0.52; P=.0021), privately insured (AMR=0.81; P=.0093), receiving prenatal care (AMR=0.72; P=.0420), residing in micropolitan (AMR=0.71; P=.0070) or small-town areas (AMR=0.67; P=.0095), or residing in neighborhoods with higher household food-stamp receipt (AMR=0.78; P=.0424).
conclusionsThe mean daily THC purchased during pregnancy exceeded therapeutic dosing ranges established for FDA-approved cannabinoid formulations in nonpregnant adults and was particularly high among women initiating MC purchase prepregnancy. These findings highlight the need to understand the risks of maternal MC exposure and the drivers to high-dose use, to better guide counseling and reduce harm, particularly from high-dose THC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.